CAR T Cell Treatment: How It Works, Results and What to Expect

CAR T cell treatment is a personalised form of immunotherapy in which a patient’s own T cells are collected, genetically modified to recognise cancer cells, and returned by infusion. It can provide an important option for selected blood cancers that have returned or not responded to standard treatments, but it requires careful assessment and specialist follow-up.

Overview: What Is CAR T Cell Treatment?

CAR T cell treatment is an advanced form of cancer immunotherapy. It uses T cells, a type of white blood cell that helps the immune system respond to threats. Doctors collect these cells from the patient, modify them in a laboratory so they can recognise a target on cancer cells, and then give the cells back through an intravenous infusion.

The term CAR means chimeric antigen receptor. This is the engineered receptor added to the T cells. Once infused, CAR T cells can identify cancer cells carrying the target antigen and activate an immune response against them. The treatment is currently used primarily for selected blood cancers rather than most solid tumours.

CAR T-cell therapy is not the right treatment for every person or every cancer. It is usually considered when a cancer has relapsed after treatment or has not responded sufficiently to other therapies. Decisions are made by a specialist cancer team after reviewing the diagnosis, previous treatments, general health and treatment goals.

Who May Be a Candidate for CAR T-Cell Therapy?

Eligibility depends on the approved CAR T-cell product available in a country, the exact cancer subtype and the person’s clinical situation. CAR T cell treatment may be considered for some people with certain B-cell lymphomas, acute lymphoblastic leukaemia, multiple myeloma and other specific blood cancers. The eligibility criteria can vary between diseases and treatment programmes.

Before recommending treatment, the team assesses blood tests, organ function, performance status, active infections, cancer burden and the pace at which the disease is progressing. Previous treatments, including chemotherapy, targeted therapy, immunotherapy, radiotherapy or stem cell transplantation, are also considered. Some people need treatment to control the cancer while their CAR T cells are being manufactured; this is often called bridging therapy.

A multidisciplinary discussion is important because the process involves haematology or oncology, cellular therapy specialists, transfusion services, intensive care support, neurology and infection specialists when needed. Patients should also discuss practical issues such as caregiver support, travel, time away from usual activities and the need for close follow-up after infusion.

How CAR T Cell Treatment Works: Step by Step

The first step is leukapheresis, a procedure that collects white blood cells from the blood. Blood is passed through a machine that separates and gathers the needed cells, while the remaining blood components are returned to the body. The collected T cells are then sent to a specialised laboratory for modification and expansion.

During manufacturing, the cells are equipped with a receptor designed to detect a particular antigen on cancer cells. The modified cells are multiplied until there are enough for treatment. Manufacturing and quality testing take time, so the care team monitors the patient closely during this period and may use bridging therapy where appropriate.

Shortly before the CAR T-cell infusion, many patients receive lymphodepleting chemotherapy. This is not intended to eliminate the cancer on its own; it helps create an environment in which the infused cells can expand and function. The CAR T cells are then given through a vein, usually as a single infusion. The infusion itself may be relatively brief, but the monitoring that follows is an essential part of treatment.

CAR T-cell therapy is a specialised cellular treatment and is different from standard chemotherapy or a stem cell transplant. While both may be part of care for blood cancers, they have different purposes, preparation steps and potential risks.

Recovery Timeline, Monitoring and Follow-Up

Recovery is individual, but the first days and weeks after infusion are the period when side effects are most likely to occur. Depending on the treatment plan, disease and local protocols, patients may remain in hospital or stay close to the treatment centre for regular assessments. The team checks temperature, blood pressure, oxygen levels, neurological function and blood counts.

Blood counts can stay low for weeks or sometimes longer, increasing the chance of infection, anaemia or bleeding. Follow-up may include transfusions, infection prevention measures, growth-factor support when appropriate and regular laboratory testing. Patients should follow their team’s instructions about hygiene, medicines, activity, food safety and contact with people who are unwell.

Response assessments are planned according to the cancer type and may involve blood tests, bone marrow testing or imaging. Some people see signs of response within the first month, while a fuller assessment may occur later. Ongoing follow-up is needed because the team monitors both cancer control and delayed effects on immunity.

For international patients, Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals can assess and provide coordinated care for suitable candidates receiving CAR T-cell therapy.

Benefits, Limits and Possible Side Effects

A potential benefit of CAR T cell treatment is that it uses living immune cells that may continue to identify cancer cells after infusion. In selected patients whose cancer has returned or resisted other therapies, treatment can produce a complete remission or a meaningful reduction in cancer. However, response is not guaranteed, and some cancers do not respond or can return after an initial response.

The best-known early complication is cytokine release syndrome, or CRS. It occurs when activated immune cells release inflammatory signals. Symptoms may include fever, fatigue, low blood pressure, fast heart rate or breathing difficulties. CRS can range from mild to severe, and prompt recognition in an experienced treatment centre allows the team to provide supportive care and medicines when needed.

Some patients develop neurological effects, sometimes called immune effector cell-associated neurotoxicity syndrome. Symptoms can include headache, confusion, difficulty speaking, tremor, drowsiness or seizures. These effects require urgent clinical assessment. Other possible concerns include infections, low blood cell counts, low antibody levels and, less commonly, effects on organs or abnormal immune activation.

The care team explains expected risks in the context of the individual’s cancer and health. Report new symptoms promptly rather than trying to manage them alone, especially during the first weeks after infusion.

What Are the Downsides of CAR T-Cell Therapy?

The main downsides of CAR T-cell therapy are the time and preparation it requires, the possibility of serious immune-related side effects, and the fact that it may not work for every patient. Cell collection and manufacturing can take weeks, and some people need interim treatment to keep the cancer controlled while waiting. The process also involves frequent appointments and a period of close monitoring near the treatment centre.

CRS and neurological toxicity are the side effects that most often require urgent observation and treatment. Low blood counts and reduced immune protection can persist beyond the initial recovery period, making infection prevention and follow-up especially important. The patient may need transfusions, preventive medicines or immunoglobulin replacement in some circumstances.

There are also emotional and practical demands. Patients and caregivers may need to arrange travel, accommodation, time away from work and help at home. A specialist team can help clarify what support is likely to be needed and whether other treatments may be more suitable.

How Long Does It Take for CAR T-Cell Therapy to Work?

CAR T cells begin expanding and acting in the body soon after infusion, but the time to a measurable response differs by cancer type and individual circumstances. In some people, blood tests, symptoms or imaging suggest a response within several weeks. Formal response assessments are often performed around one month after treatment and repeated over time.

An early scan or blood test does not always tell the complete story. Inflammation related to immune activity can complicate interpretation, and the treating team considers results alongside symptoms, examination findings and the expected pattern for that specific disease. Follow-up is therefore essential even when a person feels well.

People should ask their treating specialist when assessments are planned and what results would mean for their care. If the cancer does not respond or progresses, the team can discuss other approaches, which may include targeted medicines, clinical trials, chemotherapy, radiotherapy or bone marrow transplantation for appropriate patients.

Can CAR T Cells Completely Cure Cancer? What Is the Success Rate?

CAR T cells can lead to complete remission in some patients, and certain remissions may be long-lasting. However, doctors usually avoid promising a cure because outcomes vary substantially according to the cancer type, its biological features, the amount of disease present, prior treatments, the specific CAR T-cell product and the person’s overall health.

There is no single success rate for CAR T-cell therapy. Clinical trial and real-world results differ among lymphoma, leukaemia and multiple myeloma, and they also depend on whether success means a partial response, complete remission, remission lasting for a defined period or longer-term survival. A specialist can provide the most meaningful information by discussing results for the patient’s exact diagnosis and treatment history.

Even after a complete response, regular review remains important because relapse can occur. Conversely, an incomplete early response does not always determine the final outcome. Care plans should be personalised and updated as response data become available.

When to Seek Medical Care

Anyone considering CAR T cell treatment should seek assessment from a haematologist or medical oncologist with experience in the relevant blood cancer. A prompt specialist review is particularly important when a known lymphoma, leukaemia or myeloma has returned, is progressing or is not responding to the planned treatment.

After CAR T-cell infusion, patients should contact their treatment team urgently for fever, chills, shortness of breath, chest discomfort, severe weakness, persistent vomiting, bleeding, confusion, trouble speaking, severe headache, new tremor, seizure-like activity or any sudden worsening in how they feel. These symptoms can have several causes, but they need timely medical evaluation.

Patients should keep the treatment centre’s emergency contact information available and tell emergency clinicians that they have received CAR T-cell therapy. They should not delay care because they are unsure whether a symptom is treatment-related.

Frequently asked questions

Is CAR T cell treatment a type of chemotherapy?

No. CAR T cell treatment is a type of cellular immunotherapy that uses modified T cells to recognise cancer cells. Many patients receive short-course lymphodepleting chemotherapy before infusion, but this preparation is different from the CAR T-cell treatment itself.

How long does the CAR T-cell treatment process take?

The overall process often takes several weeks, starting with cell collection and continuing through manufacturing, preparation treatment, infusion and close monitoring. The exact timing depends on the CAR T-cell product, the treatment centre and whether bridging therapy is needed.

What are the downsides of CAR T-cell therapy?

Downsides include the possibility of serious immune-related side effects, prolonged low blood counts, infection risk and the need for close follow-up. It also requires time for cell manufacturing and may not produce a response in every patient.

How long does it take for CAR T-cell therapy to work?

CAR T cells can begin working soon after infusion, but measurable responses are commonly assessed over the following weeks and months. The team schedules blood tests, scans or bone marrow tests based on the specific cancer being treated.

Can CAR T cells completely cure cancer?

CAR T-cell therapy can produce complete and sometimes durable remissions in selected patients, but it cannot guarantee a cure. The likelihood of long-term disease control depends on the cancer subtype, prior treatments, disease characteristics and individual health factors.

What is the success rate of CAR T-cell therapy?

There is no single success rate because results differ across diseases, CAR T-cell products and definitions of response. A treating specialist can explain the evidence most relevant to a person’s exact diagnosis, treatment history and current condition.

References

• National Cancer Institute
• U.S. Food and Drug Administration
• American Society of Hematology
• European Society for Medical Oncology
• Leukemia & Lymphoma Society

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.